Our Hyaluronan-Enhanced, Polymeric Transcatheter Aortic Valves are inspired by nature and perfected by engineers.
YoungHeartValve has 3 patents approved or pending in the US and worldwide
Lorem ipsum doler sit.
Lorem ipsum doler sit.
YoungHeartValve successfully raised double the normal amount for an NIH SBIR Phase 1
Founded by leaders in the structural heart space, we are changing the future of heart valve intervention. Our valves eliminate the need for animal tissue.
YoungHeartValve’s RejuvenateTM TAVR device incorporates hyaluronan into its leaflets, creating a proven thrombosis- and calcification-resistant biomolecular interpenetrated network.
Our valves are engineered for lifetime patient care without the need for multiple interventions and everyday medication management.
There are many options for heart valves available today, but none quite like ours.
YoungHeartValve's technology is truly the wave of the future for people living with valve disease. Longer lasting valves with no reliance on anticoagulants is finally achievable.
The hyaluronan molecular network mimics the body's own valve, which provides durability approaching that of mechanical valves.
YHV's biopolymer valves are built for endurance. Testing done so far shows success rates that will last a lifetime instead of needing repeat interventions.
Balloon expansion is easier on the surrounding tissue and leaflets, which allows our biopolymer valves to fit more naturally, decreases risk, and increases patient safety and outcomes.
Our unique, patent-pending technology allows for less leakage caused by space left between natural heart tissue and the valve replacement.
Our biopolymer valves have proven hemocapatibility leading to fewer problems with haemolysis, thrombosis and calcification.
Because our biopolymer valves do not require animal tissue or time-intensive labor, the manufacturing is incredbly scalable.
YoungHeartValveTM are investigational, not for clinical use, and not available for sale.
© 2024. YoungHeartValve. All Rights Reserved.